All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

JAK Inhibitors Persist, While Novel Agents Aim for Disease Modification in Myelofibrosis

October 16th 2025

Aaron Gerds, MD, MS, discusses the clinical applications of each of the FDA-approved JAK inhibitors for the treatment of patients with myelofibrosis.

Novel Immunotherapy Combination Destroys Colorectal Liver Metastases

October 16th 2025

Researchers from UCSF discovered that a combination of immunotherapies can reprogram the immune environment of colon cancer tumors in the liver.

Teclistamab Plus Daratumumab Boosts Survival in R/R Myeloma

October 16th 2025

Teclistamab plus daratumumab improved progression-free and overall survival in relapsed/refractory multiple myeloma after 1 to 3 lines of therapy.

Pembrolizumab Plus Chemo With or Without Bevacizumab Improves OS in Platinum-Resistant Ovarian Cancer

October 16th 2025

Pembrolizumab plus chemotherapy with or without bevacizumab improved overall survival in platinum-resistant ovarian cancer.

Study Shows ChatGPT Struggles With Patient-Specific Queries, Novel Therapies in Hematologic Malignancies

October 16th 2025

A study found ChatGPT 3.5 was more likely to give incomplete or inaccurate answers to specific hematologic malignancy queries vs general questions.

FDA Grants Orphan Drug Designation to MNV-201 for Myelodysplastic Syndrome

October 16th 2025

MNV-201 has received orphan drug designation from the FDA for use in myelodysplastic syndrome.

Toripalimab Plus CCRT Generates 100% ORR, But Safety Concerns Warrant Additional Research in Locally Advanced Cervical Cancer

October 16th 2025

Toripalimab plus CCRT produced a 100% ORR in locally advanced cervical cancer, although the regimen was associated with radiation-related AEs and irAEs.

Acalabrutinib Plus Lenalidomide and Rituximab Is Safe and Active in Untreated Follicular Lymphoma

October 15th 2025

Acalabrutinib plus lenalidomide and rituximab displayed activity and had a tolerable safety profile in first-line follicular lymphoma.

Izalontamab Brengitecan Data Reinforce the Value of ADCs in Advanced Urothelial Carcinoma

October 15th 2025

Izalontamab brengitecan showed signals of activity in patients with pretreated locally advanced or metastatic urothelial carcinoma.

Expanding Radioligand Options Redefine mCRPC Management and Individualize Patient Care

October 15th 2025

Alicia Morgans, MD, MPH, discusses the role of radioligand therapies for mCRPC and the importance of shared decision-making in prostate cancer management.

Adjuvant Chemoradiotherapy Yields 10-Year OS and RFS Advantages in High-Risk Endometrial Cancer

October 15th 2025

Chemoradiotherapy improved survival vs radiotherapy alone in the adjuvant setting in high-risk endometrial cancer, particularly in p53-abnormal disease.

Genetic “Trojan Horse” Selectively Kills Cancer Cells Linked to Kaposi’s Sarcoma

October 15th 2025

Targeted gene therapy kills herpesvirus-linked cancer cells, sparing healthy tissue

FDA Approval of TAR-200 Represents Potential Bladder-Sparing Option in BCG-Unresponsive NMIBC

October 15th 2025

Joseph Jacob, MD, MCR, discusses the significance of the FDA approval of TAR-200 for BCG-unresponsive non–muscle-invasive bladder cancer.

FDA Grants Fast Track Status to NG-350A for pMMR Locally Advanced Rectal Cancer

October 15th 2025

NG-350A has been awarded fast track designation from the FDA for rectal cancer and is under further evaluation in the FORTRESS trial.

Rucaparib Maintenance Therapy Displays Activity in Pretreated Recurrent/Metastatic Endometrial Cancer

October 15th 2025

Maintenance rucaparib showed efficacy in recurrent/metastatic endometrial cancer after the completion of first- or second-line chemotherapy.

EU Approval Sought for Relacorilant in Platinum-Resistant Ovarian Cancer

October 14th 2025

The approval of relacorilant for use in patients with platinum-resistant ovarian cancer is sought from the European Medicines Agency.

PEACE-3 Data Add to Expanding Evidence Clarifying Radium-223 Use in mCRPC

October 14th 2025

Alicia Morgans, MD, MPH, discusses data from the PEACE-3 trial that support the use of radium-223 plus enzalutamide in patients with mCRPC.

‘Google Maps’ Approach to Revolutionize Lung Cancer Treatment

October 14th 2025

Researchers developed a way to predict how lung cancer cells will respond to different therapies, allowing for more effective individualized treatment.

64Cu-SAR-bisPSMA Bests SOC 68Ga-PSMA-11 PET/CT in Detecting PSMA-Positive Prostate Cancer Lesions

October 14th 2025

64Cu-SAR-bisPSMA displayed a higher detection rate of PSMA-positive prostate cancer lesions vs 68Ga-PSMA-11 PET/CT in patients with low PSA levels.

Tucatinib Plus Trastuzumab and Pertuzumab Maintenance Improves PFS in HER2+ Metastatic Breast Cancer

October 14th 2025

Combining tucatinib with trastuzumab and pertuzumab improved PFS as first-line maintenance in patients with HER2-positive metastatic breast cancer.